Cite

Combination Cancer Immunotherapy Targeting TNFR2 and PD-1/PD-L1 Signaling Reduces Immunosuppressive Effects in the Microenvironment of Pancreatic Tumors

MLA

X. Zhang, et al. “Combination Cancer Immunotherapy Targeting TNFR2 and PD-1/PD-L1 Signaling Reduces Immunosuppressive Effects in the Microenvironment of Pancreatic Tumors.” HPB, vol. 24, Jan. 2022, pp. S306–07. EBSCOhost, https://doi.org/10.1016/j.hpb.2022.05.646.



APA

X. Zhang, M. Lao, Y. Duan, J. Xu, H. Yang, H. Ying, K. Sun, X. Bai, & T. Liang. (2022). Combination Cancer Immunotherapy Targeting TNFR2 and PD-1/PD-L1 Signaling Reduces Immunosuppressive Effects in the Microenvironment of Pancreatic Tumors. HPB, 24, S306–S307. https://doi.org/10.1016/j.hpb.2022.05.646



Chicago

X. Zhang, M. Lao, Y. Duan, J. Xu, H. Yang, H. Ying, K. Sun, X. Bai, and T. Liang. 2022. “Combination Cancer Immunotherapy Targeting TNFR2 and PD-1/PD-L1 Signaling Reduces Immunosuppressive Effects in the Microenvironment of Pancreatic Tumors.” HPB 24 (January): S306–7. doi:10.1016/j.hpb.2022.05.646.